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Abstract We conducted a psychotherapeutic examination of the use of definitive drug testing
(liquid chromatography with tandem mass spectrometry) in the treatment of substance use
disorders (SUD). Employing a generic qualitative method (Caelli et al. in International
Journal of Qualitative Methods, 2(2), 2003; Merriam, 2009) we asked SUD counselors to
provide narratives about cases where drug testing had revealed new or unexpected information
about clients’ drug-taking behaviors. Semi-structured interviews with 12 SUD counselors were
conducted by phone and analyzed for themes derived from the literature. These counselors
reported many new positive drug tests in clients previously believed to be adherent with
treatment. Key themes assessed in counselors’ narratives included initial client denial that was
often followed by later acknowledgement of relapse and increased motivation, at times
presenting new opportunities for clients to engage in treatment and enhance the therapeutic
alliance. These results suggest that definitive drug testing can be used in a non-stigmatizing
and therapeutic manner.
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Drug testing is an increasingly important component of the treatment of substance use
disorders (SUD) in a variety of settings. For example, some of the commonly cited purposes
of drug testing in the treatment of SUD are listed in the recent American Society of Addiction
Medicine White Paper on drug testing (ASAM 2013). They include: verification of self-
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reports, confirmation of diagnoses, identification of denial and minimization of drug and
alcohol use, enhancement of motivation for treatment, measuring biological adaptation,
assisting in the development of treatment planning, monitoring of treatment response, docu-
mentation of treatment effectiveness and outcomes, supporting of client advocacy by validat-
ing abstinence from alcohol and drug use, and validation of adherence in taking
prescribed controlled substances. In this view, linking drug testing with psychological
variables associated with the treatment of SUD, such as denial (Blume and Marlatt
2009; Levin 1998) and motivation (Prochaska et al. 1992), suggests a potential
psychotherapeutic role of drug testing.
This recent reconceptualization of drug testing is striking given its historical roots in a
forensic model, such as in workplace and criminal justice settings (Substance Abuse and
Mental Health Services Administration [SAMHSA], 2012), and as such may carry with it
some stigma that should be considered in clinical and therapeutic contexts (Reisfield 2014;
SAMHSA 2011). In contrast to the forensic use of drug testing with its focus on public safety,
such as keeping intoxicated truck drivers off the road, the goal of clinical drug testing is on
improving health outcomes of the patient (SAMHSA 2012). Moreover, the forensic model
relies largely on immunoassay (IA) technology, which while sufficiently suited to its original
purpose lacks the sensitivity and specificity of definitive, mass spectrometry drug testing. Mass
spectrometry (e.g., gas chromatography mass spectrometry [GC-MS] or liquid chromatogra-
phy tandem mass spectrometry [LC-MS/MS]) was traditionally used to confirm positive
results of IA tests in a sort of two-step process, which is why it has been historically referred
to as Bconfirmatory testing.^ However, when medically necessary, drug testing can be
performed directly with mass spectrometry, bypassing the limitations of the IA step.
Definitive drug testing is more specific and sensitive than IA and is prone to much fewer
clinically false negatives and positives (Pesce et al. 2010; Reisfield et al. 2009). Definitive drug
testing may be an important tool in clinical settings and in the treatment of SUD (ASAM 2013;
Gourlay et al. 2012; Owen et al. 2012).
Potential obstacles to drug testing have been acknowledged in the literature,
including concerns of stigmatizing clients, burdening the therapeutic relationship, or
possible legal consequences for clients (Reisfield 2014; Gourlay et al. 2012;
SAMHSA 2011). As SUD are already prone to many sources of stigma (Earnshaw
et al. 2013), any investigation of the potential therapeutic impact of drug testing
should include consideration of potential stigma and other obstacles. Few studies have
examined the clinical impact of drug testing, (Clancy et al. 2013; Reisfield et al.
2007), and to our knowledge none have specifically investigated the potential psy-
chotherapeutic role of drug testing in the treatment of SUD. Thus, the focus of this
paper is to address this need through a generic-qualitative (Caelli et al. 2003;
Merriam 2009) examination of how drug testing may impact treatment at the
individual level, from the point of view of counselors’ work with their clients. The
purpose of this study has two components: The first is to provide some insights
from SUD counselors, through our own psychotherapeutic lens, to other counselors
who are, or are considering, integrating clinical drug testing into their work with
clients. The second purpose is to provide preliminary data to help generate hypotheses
for future studies as part of a progression toward further developing this line
of inquiry.
It should be noted that, in many states, counselors are not authorized to independently order
clinical laboratory tests (including drug testing). But, members of a clinical team can use a
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baseline understanding of drug testing to help understand this objective data about their clients.
Learning how to understand drug test results may create an opportunity for use in therapy
efforts with clients/patients.
Current Study
In order to help develop a greater understanding of how drug testing may impact the treatment
of SUD, we sought detailed narratives and perspectives from substance-use counselors about
the clinical use of definitive drug testing (LC-MS/MS) and its potential impact on their work
with their clients. The narrative data presented here is part of a larger study that included
treatment plan, patient-outcome, and drug-testing knowledge questions. A critical goal of the
present study was to let the narratives unfold, potentially to discover the unexpected. An
important and common feature among these vignettes was that they represented a transitional
period in this cohort when a facility-wide change was implemented, switching drug testing
methods for all clients from a laboratory employing the forensic model in which only IA-
positives were confirmed by mass spectrometry, to a laboratory utilizing a definitive model, in
which all specimens were processed only through LC-MS/MS. Given the power of the newer
testing methodology, a greater frequency of actual positive test results in previously Bnegative^
individuals was anticipated. However, what was unknown was how clients and their coun-
selors would respond, or the potential impact on the therapeutic community as a whole. An
unanticipated response was tension in the community during the transition, the likely reaction
to many unexpected positive results discovered in clients often mandated and previously
thought to be abstinent. Indeed, as one counselor stated,
We are getting a lot more positive results right now which everybody is sort of reeling
from. It’s been very disruptive, it’s difficult, but I think it’s really important because
otherwise [how do we] know what are we actually doing? So I definitely think it’s a pro.
You know the con is obviously the learning curve because we are switching from
something that was sort of permissive so now everyone has to adjust.
There seemed to be a growing realization that the community might have to reevaluate their
culture and how they deal with denial and that there was much work remaining in order to help
clients achieve their goals of sobriety. In fact, part of the impetus for this study was the
spontaneous and passionate revelations from many counselors about how their understanding
of their clients, and their work with them, had changed in the face of the new drug testing that
provided more specific clinical data. They wanted to get their stories out and share them with
the rest of the SUD-treatment world.
Methods
In this IRB-approved study, SUD counselors volunteered at two large urban substance-use
treatment facilities, one residential and the other an outpatient program, where all clients were
concomitantly human immunodeficiency virus (HIV) positive and had recently been started
on, or switched to, laboratory-definitive LC-MS/MS drug testing from a laboratory that
employed the more traditional forensic model in which only IA positives were confirmed by
mass spectrometry. This study occurred over a period of approximately 2 months and started
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approximately 3 months after the entire facility had switched drug testing procedures.
Additionally, when these treatment facilities made the switch to LC-MS/MS, they also chose
to rely almost entirely on oral fluid testing for this purpose. Oral-fluid drug testing can provide
the advantages of easier observed collections and to pose a potentially greater obstacle to
adulteration (Conerman et al 2014; Heltsley et al 2012).
Participants
All counselors at these two settings were offered the opportunity to participate, and nearly all
did. (We say Bnearly^ because it remained unclear whether there had been a small amount of
staff turnover during the course of this study.) The inclusion criteria were that counselors had
worked directly with clients in a therapeutic capacity regarding their SUD and that the work
had included discussion of drug-test results. We considered this sampling method to be
adequate to address the purpose of the study (Merriam 2009). Each counselor was initially
asked to think of two cases in which the newly implemented definitive drug testing had an
impact on treatment. After reviewing and signing informed consent, counselors were contacted
by phone, at the time and number of their preference, by a trained research assistant utilizing a
semi-structured interview and instructed to not reveal any identifying information about their
clients. With the counselors’ permission, interviews were recorded and transcribed. Counselors
were told that the interview would take approximately 30 min and that they would be
compensated $50 each for their time.
Residential Facility The majority of clients in the residential facility were mandated by the
criminal justice system for substance treatment, typically for 12 to 18 months. All clients had a
history of SUD and were HIV positive. Many entered the program straight from a detoxifi-
cation program (Bdetox^). Frequency of testing included a baseline drug test for every client,
but thereafter as medically indicated (e.g., based on risk factors such as history and aberrant
behaviors). After completion of the program, many clients had the opportunity to remain at the
facility, and some had been there approximately 2 years. The residential facility referred to
itself as a modified therapeutic community within a nursing home for people with AIDS,
employing a number of modalities, including individual and group therapy sessions scheduled
throughout the day. The intensity of treatment, such as the number of groups assigned to a
given client, was based on individualized assessments. A quasi-harm-reduction model was
employed wherever possible as long as clients were making progress toward the goal of
sustained abstinence. As clients progressed through the program, they acquired more inde-
pendence and privileges, including the ability to leave the residence under certain conditions.
Clients who had adherence issues could be assigned more frequent therapy sessions, additional
education, closer monitoring, and potentially decreased privileges such as temporary suspen-
sion of weekend passes. Drug tests were ordered and interpreted by physicians as medically
indicated, and the results were shared with staff and clients wherever appropriate.
Outpatient Facility As with the residential program, many clients were court mandated to
treatment in this Adult Day Treatment Program and all were HIV positive and had a history of
SUD. Some clients were admitted directly from the residential program, and many of the
attributes of this population were the same as for the residential program described above.
Level of participation varied, whether weekly, daily, or part of a day. There was a variety of
substance-related and health education groups and individual therapy. Drug testing occurred
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randomly and as medically indicated, which produced an average frequency of approximately
once per week.
Materials
A semi-structured interview was designed by three PhD-level psychologists (first, sixth, and
last authors) experienced in substance-use disorders and drug testing (see Appendix for the full
interview form). Some interview items were open-ended to illicit narratives about clinical
cases (Merriam 2009), and some were drawn from the literature (ASAM 2013; Clancy et al
2013; Gourlay et al. 2012; Reisfield et al 2007). The main scripted prompt that initiated the
counselors’ narratives was, BWithout revealing any identifying information, please tell a story
in which a client was recently started on or switched to the new LC-MS/MS laboratory drug
testing and where that change had an impact.^ This open-ended item was designed to illicit the
sorts of narratives that counselors had spontaneously reported to the first and last authors
during educational programs related to drug testing. The educational programs are part of the
usual services made available by the drug-testing laboratory and were requested by the medical
director of the treatment center (second author) in response to many new questions from
counselors about the testing. An experienced research assistant was trained by the principle
investigator on conducting the interview by phone. Mock interviews were repeated until the
assistant demonstrated an adequate level of consistency.
Procedures
Substance-use counselors volunteered via sign-up sheets and signed informed consent forms
available at staff meetings at the two treatment locations. Counselors were interviewed via
telephone and informed that the interview would take approximately 30 min to complete.
Counselor interviews were recorded, with permission (all counselors consented to recording),
using an ESONIC Mobile Phone Call Recorder & Voice Recorder. Following demographic
questions, the core of the interview consisted of the open-ended prompt for narratives,
followed by optional clarifying prompts, and finally specific items related to treatment-plan
effects and client outcomes (not reported here).
Analytic Approach
The interviews were transcribed by a research assistant and cleaned of any potential identifying
information. In addition to tabulating responses to discrete interview questions, transcripts were
coded for thematic content by two PhD-level clinical psychologists (first and last authors) with
expertise in substance-use and drug testing. A priori guidance for thematic content was
provided byASAM (2013), and in particular the potentially psychotherapeutic themes of denial
(Blume andMarlatt 2009; Levin 1998) and motivation (Prochaska et al. 1992) were of interest.
Thematic a priori guidance was also provided by the initial spontaneous reports from coun-
selors, which, according to our clinical-psychologist perspective, spoke to potential therapeutic
relationship effects (Kelley et al. 2014; Levin 1998). These three a priori themes were also built
into the clarifying prompts of the semi-structured interview, increasing the likelihood that they
would be represented in the data. The fourth theme of potential stigma was not built into the
interview but was suggested by the literature (Earnshaw et al. 2013; Reisfield 2014; SAMHSA
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2011) and emerged from initial reviews of the narratives, as agreed by the two reviewing
psychologists. The coding by the two reviewing psychologists based on these four themes was
in complete agreement. The first author selected excerpts based on this coding, which were then
approved as being consistent with and representative of the coding by the other two psycho-
logist authors. Coding was not mutually exclusive, i.e., a given excerpt could represent multiple
codes. The coded themes provided organizational and conceptual structure to the presentation
of the data but were not meant to represent all possible themes contained in the narratives
(Merriam 2009). The number of times each coded them occurred was not counted, as the
relative frequency of each of these themes was not considered to be interpretable or meaningful.
To enhance scientific rigor (Caelli et al. 2003; Merriam 2009) and help ensure the clinical
relevance and representativeness of the selected data, a subset of excerpts (judged as repre-
sentative by the first author) were presented to a group of 10 of the original participant
counselors and the medical director for feedback on whether the excerpts and associated
themes had captured what they felt was important and useful for the purpose of this study. The
group represented merely those that were available to attend on a date of convenience.
Confirmation from this group was obtained verbally and noted by the first author. While the
feedback process did spontaneously illicit some additional minor detail, none was deemed to
substantively alter the data.
As this is one of the first studies of its type, the data was treated as descriptive and
exploratory; inferential statistics were not utilized. Demographics are represented as frequen-
cies, means, and percentages. A secondary analysis of client cognitive change was based on
the temporal stability of client denial. This is useful because the ways that individuals may
move in and out of denial is relevant to better understanding factors that could influence
therapeutic relationships (Levin 1998). Only descriptive results were provided for this mea-
sure, as the sample size would not permit calculation of meaningful correlations.
Results
Counselors (n=12) were split evenly among the two settings, and their demographics were
comparable with the exception that counselors were, on average, older in the residential
compared with outpatient settings, with an average age of 48.7 and 36.6 years, and an average
number of months working with clients of 136.5 and 71.5 months, respectively. The complete
sample of counselors was 75 % female, 25 % African American, 25 % Caucasian, 16.7 %
Latino, and one third Bother.^ Eight had master’s degrees, three had bachelor’s degrees, and
one had not completed high school. Four counselors were social workers, one was a psychi-
atric nurse practitioner, and the rest described themselves as counselors or case workers. All
participants described their specialty as related to substance-use, worked directly with clients
as counselors, work that typically included discussion of drug-test results. Counselors provided
vignettes encompassing 24 unique clients, with an average age of 51.4 years; 37.5 % were
female, and 75 % were court-mandated to treatment. The average duration of SUD was
~28 years (range 10–45), with the self-reported primary drug of choice being 41.7 % crack
cocaine, 33 % heroin, 20.8 % powdered cocaine, and 4.2 % prescription-type drugs. Most
clients had histories of using multiple illicit substances.
Narrative Data An important element common to most of the vignettes was of newly
discovered relapses or continued use being identified with the switch from the IA based
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laboratory to the LC-MS/MS laboratory. This was not unexpected given the greater sensitivity
and specificity of LC-MS/MS testing, and that counselors were prompted to think of cases
where the change in drug testing was associated with impact on treatment. Interestingly,
however, clients had, in some cases, apparently become accustomed to the previously
employed IA model of testing, expecting their continued use to go undetected. Importantly,
initial denial of test results was common and at times energetic, perhaps owing in part to legal
consequences or stigma. As one counselor illustrated,
I see a lot of the residents, especially this particular young lady, she figured that if she
knew her test was Monday and she did stuff on the weekend that nothing would show.
This counselor described the client’s first encounter with the newly implemented LC-MS/
MS testing, reporting:
…I sat her down, I had the results in my hand, and I asked her how she was doing, kinda
ease in to it. Asked her where did you go? How are things going? Because your tox
came back positive for whatever. She got very upset very agitated. Walked out the office
was cussing me out saying I was lying…
However, in many cases the initial denial subsided as counselors developed confidence in
their understanding of the testing methodology and relayed education about the improved
accuracy and sensitivity of the tests that they had received from educational services provided
by the newly employed lab. As one counselor explained, definitive drug testing could provide
an opportunity to:
…foster healthy conversations with clients about their drug use. You can kind of catch
people when they are not telling the truth or when they are in denial. So if someone is in
denial you can kind of work on helping them in another way.
The change in testing methodologies was not always clinically impactful. For example, in
one case in which the client was known for a long history of dispositional intransigence,
neither the newer testing nor enhanced therapeutic and educational efforts seemed to lead to
any meaningful changes, with an incarceration being the final result at the time of this study.
Nevertheless, in most cases, clients who had started testing positive, often for cocaine and
alcohol, quickly began testing negative, suggesting increasing abstinence as they came to
accept the validity of the newer testing methodology. Many of the counselors indicated a
favorable view of this change, as they came to realize that they were seeing their clients’
substance-use behaviors more clearly.
Counselors also spoke of how newly revealed continued use at times impacted the
therapeutic community. One counselor told a story of a popular female client who had been
viewed by the community as a Bmodel of sobriety^ because she had consistently tested
negative prior to implementation of the LC-MS/MS definitive laboratory. The counselor
explained being surprised that:
…she was not ready to stop using…we were able to pick up on that after we caught her
relapses…she was probably doing it before but because of the [previous IA-lab] testing
we were unable to pick it up. Whatever games she played before it didn’t work [any
more].
Initially her denials were dramatic but eventually she entered what may have been one of
her first true periods of abstinence, as suggested by consistently negative LC-MS/MS test
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results. Nevertheless, during a weekend pass she died tragically following a relapse associated
with marital discord. Importantly, the counselor explained,
Her peers look at her and see her and see that they might have learned a lesson. They
think ‘wow, I thought she was doing good (sic) but she continued to relapse.’ …
knowing that she was continuing to use…they probably learned a lesson because there
is a saying in the room that some of us will die for others to live…
Initially, pushback from the community created stress among the staff, though most began
to see it as an opportunity to help improve outcomes with clients. In many cases, counselors
indicated that they recognized a new level of motivation among their clients, sometimes
accompanied by a deeper commitment to the program and to therapy.
In some cases, initial denial that seemed to be related to potential legal consequences turned
out to belie more personal and emotional layers that eventually may have led to enhancing the
therapeutic relationship. One counselor recalled working with a mandated 50-year-old female
client who was being treated for a history of crack cocaine use. IA tests performed by the
criminal justice system had been coming up negative weekly, but the treatment center found
cocaine positive with LC-MS/MS (likely a result of a large difference in sensitivity between
the two testing methods). Initially she denied use, possibly encouraged by the negative test
results coming from criminal-justice, and also potentially related to her fear of legal conse-
quences. But ultimately the center was able to continue working with her, and her denial gave
way to greater honesty and making further progress with her recovery. As the counselor stated,
the positive cocaine result with LC-MS/MS was:
…a catalyst therapeutically as far as acknowledging that there was a recent relapse and
figuring out what we now had to do to move forward.…I think that she maybe opened
up a little bit more about guilt and disappointment in herself. I think there was a
vulnerability that happened but it was therapeutically useful.
As a result of the relapse, the criminal justice system added 2 months to her treatment
mandate but she did not return to prison. She was given more structure and monitored more
closely. The counselor indicated she became more engaged in treatment. By the time of this
data collection, she had remained abstinent for several months, as indicated by LC-MS/MS
testing, and was on her way to successfully completing the program.
Hidden emotional components were not always accompanied by denial. One counselor
described a 56 year-old female with long history of polysubstance since her 20s. Upon
switching from the IA lab to the LC-MS/MS lab, continued use of clonazepam was revealed
after more than a year of treatment and consistently negative IA toxicology. Upon her first
positive LC-MS/MS test for clonazepam (a common benzodiazepine) there was no denial.
Rather,
…there was a deep sense of shame and failure…she was tearful and crying and saying
the moment that she [relapsed] she wanted to go straight to her staff counselor and tell
him but she couldn’t bring herself to disappoint him in that way. …it was kind of like
she was waiting for [the positive LC-MS/MS result] to happen so she could say it.
She entered a new level of progress in her therapy, revealing old sources of emotional pain
she related to SUD. She was monitored more closely and tested negative for several months.
She recently experienced a new relapse, but remarkably, this time, she did not wait for the
positive toxicology to report it. Her previous experience had helped to build a new level of
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confidence and trust in the support from her therapist and others in the community. As a result,
this new relapse was much shorter and less intense.
As SUD may be best understood as psychobiological problems involving interplay of the
biological aspects of the drug with the personality and interpersonal world of the client,
psychotherapy focusing on substance use will often include interpersonal and relational work,
helping develop the client’s sense of self in the process (Levin 1998). Accordingly, one
counselor explained how working through the denial of a positive drug test in therapy
paralleled an emerging sense of authenticity that may have extended to new relation-
ships. The counselor recalled a mandated, 47-year-old male client with a decades-long
history of polysubstance use. He had, for the first several months in the program,
produced Bclean^ or negative urine drug tests with the traditional IA-lab testing. He
was considered a model community member until his first drug test with the newly
introduced LC-MS/MS that produced an unexpected positive result for cocaine. In
keeping with the program’s policy, he was consequently put on a 30-day privilege
restriction and required to attend more daily groups, and subject to ongoing drug
monitoring. As his counselor stated,
It was positive for cocaine and this was totally unexpected as he was one of those model
citizens of the program, he did everything and always supportive of his peers. …he
denied it…
But as the counselor explained,
One of his big issues was loneliness and not being able to connect authentically with
people…^ His counselor stated that this lack of interpersonal authenticity Bparalleled^
his inauthentic sobriety. BThen we kind of took a switch… he actually started expressing
what I believe were authentic feelings of being supported, being cared for…
The client slowly started to speak more openly in therapy about his continued substance
use, and during this time he began being more open with a romantic interest, at first
uncharacteristically revealing his HIV status and eventually his substance use problems:
…he admitted that he had a substance use problem and that he’s been in treatment, and
this cascade of disclosures and honesty came post tox (after the positive cocaine test) and
I feel like that there is a direct link…
After maintaining a period of actual sobriety, suggested by the LC-MS/MS tests, the client
was preparing for a successful discharge from the program and planning to move in with a
woman with whom he had been honest about his history.
One theme that emerged was of the utility of monitoring more closely during certain
periods of heightened vulnerability, such as during the common transition from a more highly
structured environment to less. For example, one counselor recalled working with a male client
in his 60s, with a 20-year history of incarceration and cocaine use who had recently been
mandated to an outpatient treatment setting after graduating from residential programming
where he had come directly from prison. He had tested negative for months until LC-MS/MS
was implemented, and then tested positive for cocaine. Education and intensified treatment
were provided. Legal consequences remained a possibility. Despite maintaining his initial
denials, he became abstinent or substantially decreased his use (as suggested by consistently
negative LC-MS/MS tests), which may have provided him greater opportunity to become
more invested in therapy. As the counselor recalled,
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Now, the conversations [are] becoming not only about treatment but he’s opening up and
letting me enter his personal life. He is talking about relationships he has with his
children which he never really did before…
From this counselor’s perspective, certain clients like this need some additional monitoring
during what may be high-risk transitional periods where they are slowly being reintroduced to
greater personal responsibility after a period of having their lives and the choices controlled by
others:
Once a person comes out of inpatient program and released back into the community I
think it’s sort of a shock to them. More of a shock and excitement that they are out into
the community and they are able to leave the program and go home to their apartment
like a regular person where as in an inpatient they are confined and it’s a controlled
environment.
Client Cognitive Change In order to approximate clients’ cognitive change we assessed
initial denial of unexpected definitive drug-test results, including denial of relapse or continued
use, and whether they later acknowledged it. There were 12 (50 %) clients who had initially
denied unexpected results and then later admitted to relapse or continued use. Nine clients
(38 %) continued denial throughout treatment despite positive definitive test results, and the
remaining 3 (13 %) initially acknowledged the accuracy of the results. This brief analysis
supports the notion that denial is not static but rather has temporal variability.
Discussion
To our knowledge, this is the first study of counselors’ perspectives of the impact of definitive
drug testing in the treatment of SUD. Counselors reported their experiences utilizing the results
of drug tests with their clients at a time when these treatment centers had recently switched from
an IA-based, traditional forensic model of IA based drug testing to the more sensitive and
specific definitive LC-MS/MS drug testing via oral fluid. These counselor’s narratives provided
an opportunity to explore how clinical drug testing in SUD treatment can impact denial,
motivation, the therapeutic relationship, stigma, and some of the interrelations among these.
More broadly, these counselors indicated that the switch to definitive drug testing provided
them, in many instances, with new insights into their clients’ actual drug-use behaviors and
opportunities to workwith them in newways to better help them achieve their therapeutic goals.
Identifying denial and enhancing motivation are among several potential benefits of clinical
drug testing proposed by the American Society of Addiction Medicine White Paper on Drug
Testing (ASAM 2013). These data suggest that working with denial and incorporating the
results of definitive drug testing into treatment in a non-stigmatizing manner may, in some
cases, provide the conditions for greater engagement in therapy and enhancing the therapeutic
relationship (Kelley et al. 2014). This last point is particularly noteworthy given that there has
been speculation that drug-test results in the clinical setting might unintentionally stigmatize
clients and damage the therapeutic alliance (e.g., Reisfield 2014; SAMHSA 2011). Stigma in
the context of SUD can often represent the negative attitudes of healthcare professionals that
have clinical consequences for patients (Earnshaw et al. 2013). In these counselors’ narratives,
we mainly found anticipated stigma in the form of embarrassment or shame on the part of the
clients, as reported by counselors. We were encouraged, however, that in the cases where such
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feelings were revealed, counselors found it to be an opportunity to deepen their work with
clients. Although these data are necessarily preliminary, they clearly point to the potential for
counselors and their clients to overcome potential stigma and other obstacles in order
to better utilize the objective information provided by definitive drug testing. Of note
there were descriptions in some narratives of how catching relapses and denial created
an opportunity to work with clients in new ways, such as fostering constructive
dialogues, consistent with a number of guidelines related to the use of clinical drug
testing in both substance use and chronic pain (ASAM 2013; National Institutes of
Health [NIH], 2009; Gourlay et al. 2012).
As captured in counselors’ narratives and supported by the brief analysis of client-cognitive
change, denial (Blume and Marlatt 2009; Levin 1998) appears to have temporal variability,
suggesting opportunities and targets for change in the course of treatment. Other aspects of
denial should be considered as well. For example, clients might have outwardly denied
continued use revealed by definitive drug testing, despite being aware of the truth. This might
be consistent with a fear of potential legal consequences. Alternatively, some cases of denial
may have involved self-deception, or maintaining a lack of awareness of the true extent of their
own drug-use behaviors. In this sense, shifts in denial may, at times, be associated with
changes in awareness. By extension, shifts in denial might also be related to motivation, in
that progressing through levels of readiness to change may be related to shifts in awareness and
opportunities to observe oneself engaging in new behaviors (Prochaska et al. 1992). Such
would be consistent with the perspective that the enhanced accuracy of the newly introduced
definitive testing may have led to new periods of abstinence or reduced use, as suggested by
counselors’ reports of instances in which unexpected positive test results were followed by
negative LC-MS/MS drug tests. But perhaps most interestingly, in some instances such
changes precipitated an increase in clients’ engagement in therapy, suggested at times by a
greater openness to discuss guilt or shame related to substance use and emotions around
damaged relationships (Levin 1998). In either case, it seems reasonable that any time spent in
genuine abstinence likely increases the prognosis of a better outcome over time.
A less expected but potentially important theme emerging from these counselors’ stories was that
individual differences in clients’ traits and temporal circumstances seemed to impact the clinical
effects of drug testing at times. For example, in a few cases in which the clients seemed to havemore
of an antisocial disposition or a lower readiness to change, changes in drug-use behaviors may have
been relatively superficial, appearing more connected to the immediate goal of completing the
program (Prochaska et al. 1992). However, particularly instructive was the perspective of one
counselor who identified the use of clinical drug testing as key during a potentially sensitive period
of relapse risk when clients are transitioning from highly structured and controlled environ-
ments to ones with greater autonomy. As this is not an unusual circumstance, it may
represent an opportunity for counselors to better identify changing patterns of risk
factors in their clients that could be addressed with enhanced monitoring and treat-
ment. An important area of future inquiry will be to examine a broader range of traits
and situations that impact the therapeutic effects of clinical drug testing.
Following the initial stress of adapting to the changes in testing methodology, identifying
relapses, enhancing motivation, and deepening the therapeutic relationship may have contrib-
uted to a more helpful environment for the therapeutic community as a whole. Counselors
spoke at times about how a culture develops among clients in the community in which they
share their stories, advise each other, and develop a shared perception of treatment and their
role in it. In listening to these counselors, there was a sense at times of a cultural shift in the
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client community from an attitude of Blet’s game the system^ to one of Bhow can we adapt to
actually being sober.^ This is consistent with counselors’ reports that the initial community
unrest that coincided with the introduction of the definitive drug testing eventually began to
soften. To the extent that there may have been a genuine evolution in the attitude or culture of
the community, it could have a desirable impact on the recovery efforts of individual clients.
This is a compelling notion that will, for now, remain the work of future research to explore.
Limitations and Future Directions
As the results from this qualitative study are exploratory and descriptive, caution is warranted in
interpreting them. The present findings provide some insights for counselors doing similar
work, and preliminarily support for the relevance of denial, motivation, the therapeutic rela-
tionship, and stigma in better understanding the role of clinical drug testing in the treatment of
SUD. The present findings also suggest that quantitative studies may be warranted to examine,
for example, the extent to which these effects lead to changes in treatment-plans and client
outcomes. The limited sample, while appropriate for the goals of the present study, limits the
generalizability of the findings, such as in non-urban settings or populations without mandated
clients or who are not HIV positive. Nevertheless, this first examination of counselors’
perspectives of the use of definitive drug testing in their work with substance-use clients is
consistent with that proposed by ASAM (2013) and others, warranting further investigation.
Conclusions
Counselors’ perspectives of the impact of definitive LC-MS/MS drug testing were consistent with
potential benefits outlined in a number of guidelines (e.g., ASAM 2013; NIH 2009; Gourlay et al.
2012) including the treatment goals of increasingmotivation (Prochaska et al. 1992), reducing denial
(Blume and Marlatt 2009; Levin 1998), and, by extension, enhancing the therapeutic relationship
(Kelley et al. 2014; Levin 1998). They further suggest that counselors and their clients can overcome
stigma and other potential obstacles to the therapeutic use of definitive drug testing (Reisflield 2014).
Though these qualitative results are necessarily preliminary andmust be interpretedwith caution, they
are consistent with previous work suggesting that clinical drug testing can impact treatment decisions
and patient outcomes to help optimize patient care (Clancy et al. 2013; SAMHSA2011). The current
results extend previous research by illustrating and elaborating the impact of definitive drug testing, as
a specific case of clinical drug testing, in the treatment of substance use disorders. Substance-use
counselors may be able to utilize definitive drug testing in the early identification of relapses and then
work with potential denial and stigma, enhancing motivation and the therapeutic relationship.
‘All procedures followed were in accordance with the ethical standards of the responsible
committee on human experimentation (institutional and national) and with the Helsinki
Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients
for being included in the study.’
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Appendix: Definitive Drug Testing in SUD Semi-structured Interview
Intro:
Thank you for your me today. I will try my best to keep this interview to 30 minutes or less to respect
your schedule. Your responses will be invaluable for helping us beer understand the impact of drug
monitoring in the addicon ﬁeld.
First, I want to ask a few background quesons:
I. Preliminary quesons about interviewee:
Q1: 
What is your age?   ____________ (years)
Q2: 
What is your gender?       ______ Male        ______ Female
Q3:
What ethnicity do you most idenfy with? ______ Lano/Hispanic  ______ African American/Black 
______ White
_______Asian ______ Nave American  _______________________Other(describe)  _________ Mix
_________
Q4: 
What is your role at this facility?
(Q4a) Job tle(how do you work with paents)? 
(Q4b) How long have you been doing this kind of work? _______________________________
[convert to months]
(Q4c) How long have you been at this facility? ________________________________ [convert
to months]
(Q4d) How long working with clients? _____________________________________________ 
[convert to months]
(Q4e) Profession?  
(Q4f) Specialty? 
(Q4g) Highest educaon? _____ <HS ____ GAD/HS ____ 2-yr college ____ BS/BA ____Masters 
____PhD
Q5: 
(Q5a) Do you administer, interpret, or communicate with clients about drug monitoring test results? __
Yes    ___ No
(Q5b) How oen? _______________(convert to mes per month)
II. Inial vignee queson:
Q6: 
“Without revealing any paent/client identy, please tell a story in which a paent/client was recently 
started on or switched to the new quantave LC-MS/MS laboratory drug tesng, and where that 
change had an impact.”  
III. General Prompts:
Prompt 1: 
What is the gender of the client?       ______ Male        ______ Female
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Prompt 2: 
What is the age of the client?   ____________ (best guess in years)
Prompt 3: 
Why was the client seen at this facility? What were they being treated for? 
Prompt 4: 
(P4a) Does the client have a history of drug/medicaon abuse or addicon? ______ Yes        ______ No
(P4b) Primary and other drugs of abuse/addicon:
_______________________  Primary  
__________________________________________________  Others
(P4c) How long with the abuse/addicon?  ________________________________ [convert to months]
(P3d) What kind of substance abuse treatment were they receiving? (modalies, frequency, intensity)
Prompt 5:
(P5a) Does the client have other psychiatric and medical condions? ______ Yes        ______ No  What? 
(P5b) Types of treatments?
Prompt 6: 
How long has the client been in the program/at facility?  ________________________________ 
[convert to months]
Prompt 7: 
How long have you been working with/known this client? ________________________________ 
[convert to months]
Prompt 8: 
(P8a) Did the client switch from no drug tesng or from another type of drug tesng?   _____ None    
______ Other
(P8b) If other, what type? 
Prompt 9: 
What happened when new drug tesng started?
(P9a) Did the new test provide diﬀerent informaon?   ______ Yes        ______ No
(P9b) Was a relapse caught?  ______ Yes        ______ No
(P9c) What was found?  
(P9d) How was this diﬀerent from what was found with the older tesng method? 
(P9e) Was the test result unexpected? ______ Yes        ______ No
(P9f) How were the results communicated to the paent/client? 
(P9g) When did this change begin, and what meframe does the story cover? 
Prompt 10: 
(P10a) What was the client’s response to the results? ______ Favorable    ____ Unfavorable  
_____Indiﬀerent 
(P10b: describe client’s 
response) ____________________________________________________________________________
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Prompt 11: Treatment changes
(P11a) Were any changes made to the treatment plan or goals due to drug test results?  _____ Yes
_____ No
(P11b) Educaon provided? _______ Yes        _______  No
(P11c) Change in ongoing monitoring (describe) _________ More   ________  Less 
(P11d) Change in privileges? ______ More   _________ Less
(P11e) Treatment Intensity/Frequency?  ________ Increased    _________  Decreased 
__________  Unchanged
(P11f) Change in medicaons?  (describe) 
_____________________________________________
(P11g) Status at facility?  _______ Unchanged  _________  Probaon/Warning   ________  
Discharged
Prompt 12: Therapeuc eﬀects and outcomes due to new drug tesng results
(P12a) Drug taking behaviors?  ____ Improved   ____  Worsened  
_____Unchanged
(P12b) Was a relapse caught? __ Yes   __ No
(P12c) If a relapse was caught, was it helpful?  ______ Yes        ______ No
(P12d) Aberrant behaviors? ____ Improved   ____  Worsened  
_____Unchanged
o List aberrant behaviors, which ones changed and how (provide list if needed as prompt)
(P12e) Medicaon adherence? ____ Improved   ____  Worsened  
_____Unchanged
o Details: ______
(P12f) Treatment adherence? ____ Improved   ____  Worsened  
_____Unchanged
o Details: 
(P12g) Health?  ____ Improved   ____  Worsened  
_____Unchanged
(P12h) Compliance with community rules? ____ Improved   ____  Worsened  
_____Unchanged
(P12i) Therapeuc relaonship(s)?  ____ Improved   ____  Worsened  
_____Unchanged
(P12j) Change in honesty and commitment?           ____ Improved   ____  Worsened  
_____Unchanged
(P12k) Social behavior?  ____ Improved   ____  Worsened  
_____Unchanged
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(P12l) Family relaonships? ____ Improved   ____  Worsened  
_____Unchanged
(P12m) Interacons with legal system? ____ Improved   ____  Worsened  
_____Unchanged
(P12n) Overall outcome? ________ Favorable  ________ Unfavorable
Prompt 13: 
(P13a) Did any legal consequences arise from the test results?  ______ Yes        ______ No
(P13b) Please describe 
IV. Personal Knowledge and Community impact quesons:
Q7: 
(Q7a) “I feel conﬁdent in my ability to interpret results of urine drug tests”
1 = Least conﬁdent, 5 = Most conﬁdent: 1 2 3 4 5
(Q7b)Describe diﬀerence between immunoassay drug tesng and quantave laboratory drug 
tesng  
(Q7c)Who should be tested? _______Select individuals?  _____Random individuals?  
________Everyone?
(Q7d)How oen? _________ never ________2 / yr _______ 4/yr  _______ 6/yr  __________ > 
6/yr
(Q7e)Does your facility have a drug tesng policy or protocol (please describe)? 
(Q7f)What is the purpose of drug tesng? 
Q8: 
(Q8a)What are your feelings about the newer deﬁnive LC-MS/MS laboratory tesng? Pros/Cons?
(Q8b)Overall, do you feel the newer deﬁnive laboratory tesng is: ________ Beneﬁcial  _________  
Not Beneﬁcial
Q9 (may not apply): 
(Q9a) Have you ever seen a case where a negave screen on an in-oﬃce test turned out to be a false 
negave on laboratory conﬁrmaon? ___ Yes  ____ No
(Q9b) Was catching the false negave helpful in idenfying a relapse? _________ Yes  
____________ No
(Q9c)How was therapy/treatment aﬀected and changed (please describe)?
Q10: 
How has the new laboratory drug tesng impacted the facility:
(Q10a)Staﬀ-client relaonships? ______ Improved  _______ Worsened _______ Unchanged 
(Q10b)Staﬀ conﬁdence/comfort? ______ Improved  _______ Worsened _______ Unchanged
(Q10c)Client behavior? ______ Improved  _______ Worsened _______ Unchanged
(Q10d)Other observaons? 
Thank you for your me today. 
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